NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Aeterna Zentaris Inc (NASDAQ: AEZS)

 
AEZS Technical Analysis
1
As on 26th Jul 2024 AEZS STOCK Price closed @ 5.35 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

AEZSSTOCK Price

Open 5.48 Change Price %
High 5.48 1 Day N/A N/A
Low 5.35 1 Week 0.00 0.00
Close 5.35 1 Month 0.00 0.00
Volume 1669 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
BFI 0.42 %
NVDA 113.06 %
SGMO 0.86 %
LMDX 0.02 0.00%
TELL 0.92 %
TSLA 219.80 %
VWE 0.07 %
PONO 1.72 2.38%
FCEL 0.53 %
 
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
BCAC 22.71 125.30%
CFFEW 0.11 120.00%
JCIC 22.08 116.68%
AMRS 0.14 100.00%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
ACAQ-UN 2.50 -73.49%
AXAS 0.03 -70.00%
MILEW 0.06 -53.85%
ALF 0.01 -50.00%
ALF 0.01 -50.00%
LOTZW 0.01 -50.00%
ALACW 0.01 -50.00%
BTAQW 0.01 -50.00%
 
 
AEZS
Daily Charts
AEZS
Intraday Charts
Whats New @
Bazaartrend
AEZS
Free Analysis
 
AEZS Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
AEZS Forecast July 2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
AEZS Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
AEZS Forecast2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
AEZS Other Details
Segment EQ
Market Capital 71577360.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
AEZS Address
AEZS
 
AEZS Latest News
 
Your Comments and Response on Aeterna Zentaris Inc
 
AEZS Business Profile
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina. Address: 315 Sigma Drive, Summerville, SC, United States, 29486
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service